Iruplinalkib
Iruplinalkib is Qilu Pharmaceutical's second-generation ALK inhibitor, approved in China in 2023 for ALK-positive non-small-cell lung cancer after crizotinib and in 2024 as first-line treatment.
Overview
Iruplinalkib (WX-0593) was developed by Qilu Pharmaceutical in Jinan. The NMPA approved it in June 2023 for locally advanced or metastatic ALK-positive non-small-cell lung cancer that had progressed on or was intolerant to crizotinib, and in 2024 extended the approval to first-line use after the INSPIRE phase 3 trial showed longer progression-free survival than crizotinib.
1.Iruplinalkib slips into a pocket on ALK.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| CN | 2023 | ALK-positive non-small-cell lung cancer after crizotinib; first line from 2024 |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Iruplinalkib" OR ABSTRACT:"Iruplinalkib" OR TITLE:"WX-0593" OR ABSTRACT:"WX-0593" OR TITLE:"Qixinke" OR ABSTRACT:"Qixinke") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Iruplinalkib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentGumarontinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tags china, nmpa-approved.
- TreatmentIparomlimab and tuvonralimab
Shares Qilu Pharmaceutical and the tags china, nmpa-approved.
- TreatmentVorolanib
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
- TreatmentLinperlisib
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
- TreatmentRecombinant human endostatin
Shares Non-small-cell lung cancer and the tags china, nmpa-approved.
- TreatmentFlumatinib
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
- TreatmentSurufatinib
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
- TreatmentBenmelstobart
Shares the tags china, nmpa-approved.